Combinatory ImmunoTherapy-1 (Com-IT-1) Irradiation and PD-1 Blockade in Locally Advanced / Advanced NSCLC (COM-IT-1)
Sponsor: Oslo University Hospital
Terminated
slow recruiting
Other terminated trials from Oslo University Hospital
Other Non-small Cell Lung Cancer trials with similar outcome
This PHASE2 trial investigates Non-small Cell Lung Cancer and is currently terminated or withdrawn. Oslo University Hospital leads this study, which shows 6 recorded versions since 2018 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Apr 2021 — Jul 2024 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Recruiting PHASE2
▶ Show 1 earlier version
-
Sep 2018 — Mar 2020 [monthly]
Recruiting PHASE2
First recorded
Aug 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Oslo University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .